Patent SG-11201909359Y-A (SG)
Title: Pharmaceutical composition comprising pde9 inhibitor
Inventor: SCHUCK Edgar
IPC: A61P25/28
Filed: 2018-05-30
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 06 December 2018 (06.12.2018) WIPO I PCT ill~~~~~~~~ 011101010VIIIOH olo om HE ioo iflo ow (10) International Publication Number WO 2018/221546 Al TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (51) International Patent Classification: A61K 31/444 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/JP2018/020643 (22) International Filing Date: (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/513,690 01 June 2017 (01.06.2017) US (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. [JP/JP]; 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 1128088 (JP). (72) Inventors: SCHUCK Edgar; C/O Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey, 07677 (US). LAI Robert; C/O Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL109SN (GB). SAVANT-LANDRY Ishani; C/O Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey, 07677 (US). REGE Bhaskar; C/O Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey, 07677 (US). MIYAMO- TO Mai; C/O Eisai Co., Ltd. Tsukuba Research Lab- oratories, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 3002635 (JP). KOTANI Sadaharu; C/O Eisai Co., Ltd., 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 1128088 (JP). HORIE Kanta; C/O Eisai Co., Ltd. Tsukuba Research Laboratories, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 3002635 (JP). (74) Agent: HASEGAWA Yoshiki et al.; SOEI PATENT AND LAW FIRM, Marunouchi MY PLAZA (Meiji Yasuda Life Bldg.) 9th fl., 1-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo, 1000005 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 30 May 2018 (30.05.2018) Published: — with international search report (Art. 21(3)) (54) Title: PHARMACEUTICAL COMPOSITION COMPRISING PDE9 INHIBITOR 1-1 0 (57) : The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 hibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-y1)-1-(tetrahydrofuran-3-y1)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one or pharmaceu- C tically acceptable salts thereof.